As Department of Health and Human Services (HHS) and FDA leadership continue to look for ways to boost transparency and ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

BeOne Medicines is monetizing its stake in Amgen’s first-in-class lung cancer drug Imdelltra for up to $950 million. | BeOne Medicines is monetizing its stake in Amgen’s first-in-class lung cancer ...

Seeking to build out its pipeline-in-a-product Vyvgart, Argenx is returning to its roots with plans to pursue an expanded approval in the drug’s initial myasthenia gravis indication. | On Monday, ...

With a buyout of scPharmaceuticals worth up to $360 million, MannKind is looking to dive into the large and growing field of cardiometabolic treatments. | The company touts a large U.S. market ...

Serena Williams has a new doubles partner. The 23-time Grand Slam tennis champion is working with Ro, speaking out about how ...

Despite boasting a new owner, the Indiana manufacturing plant that Novo Nordisk picked up as part of its parent company's ...

A new campaign from AbbVie highlights the “full selves” of people with conditions treated by the company’s therapies in a ...

The biopharma industry’s bid to increase drug spending in the U.K. has reached an impasse. | Talks between the U.K.

A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy ...

With three new antibiotics set to shake up the stagnant treatment landscape for uncomplicated urinary tract infections (uUTIs ...

Johnson & Johnson is spending part of its big U.S. investment at a Fujifilm Biotechnologies site. Three Indian drugmakers ...